Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claire Harrison

Showing results (111-120 of 218) with videos related to

Pageof 22
Sort By:
British Journal of Haematology|July 8, 2022
Chronic myeloid leukaemia patients at diagnosis and resistant to tyrosine kinase inhibitor therapy display exhausted T-cell phenotypePatrick Harrington, Richard Dillon, Deepti Radia, et al.
BMC Cancer|January 9, 2025
Fedratinib combined with ropeginterferon alfa-2b in patients with myelofibrosis (FEDORA): study protocol for a multicentre, open-label, Bayesian phase II trialGraham McIlroy, Charlotte Gaskell, Aimee Jackson, et al.
Future Oncology (London, England)|June 6, 2025
Indirect treatment comparison of momelotinib vs fedratinib safety in patients with myelofibrosisLucia Masarova, Srdan Verstovsek, Francesca Palandri, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 26, 2024
Machine learning enables identification of an alternative yeast galactose utilization pathwayMarie-Claire Harrison, Emily J Ubbelohde, Abigail L LaBella, et al.
Plos Genetics|March 17, 2026
Machine learning identifies novel signatures of antifungal drug resistance in Saccharomycotina yeastsMarie-Claire Harrison, David C Rinker, Abigail L LaBella, et al.
Current Biology : CB|November 5, 2022
Contrasting modes of macro and microsynteny evolution in a eukaryotic subphylumYuanning Li, Hongyue Liu, Jacob L Steenwyk, et al.
British Journal of Haematology|April 1, 2015
Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST TrialAdam J Mead, Dragana Milojkovic, Steven Knapper, et al.
Biorxiv : the Preprint Server for Biology|July 14, 2025
Machine learning identifies novel signatures of antifungal drug resistance in <i>Saccharomycotina</i> yeastsMarie-Claire Harrison, David C Rinker, Abigail L LaBella, et al.
Therapeutic Advances in Hematology|July 7, 2025
Clinical outcomes of high-risk patients with polycythemia vera after suboptimal response to first-line therapy who switched to ruxolitinib versus nonswitchers: results from the PV-Switch studySteffen Koschmieder, Clemens Schulte, Eyck von der Heyde, et al.
Haematologica|January 26, 2023
Differential inhibition of T-cell receptor and STAT5 signaling pathways determines the immunomodulatory effects of dasatinib in chronic phase chronic myeloid leukemiaPatrick Harrington, Richard Dillon, Deepti Radia, et al.
Pageof 22

Showing results (111-120 of 218) with videos related to

Sort By:
Pageof 22
British Journal of Haematology|July 8, 2022
Chronic myeloid leukaemia patients at diagnosis and resistant to tyrosine kinase inhibitor therapy display exhausted T-cell phenotypePatrick Harrington, Richard Dillon, Deepti Radia, et al.
BMC Cancer|January 9, 2025
Fedratinib combined with ropeginterferon alfa-2b in patients with myelofibrosis (FEDORA): study protocol for a multicentre, open-label, Bayesian phase II trialGraham McIlroy, Charlotte Gaskell, Aimee Jackson, et al.
Future Oncology (London, England)|June 6, 2025
Indirect treatment comparison of momelotinib vs fedratinib safety in patients with myelofibrosisLucia Masarova, Srdan Verstovsek, Francesca Palandri, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 26, 2024
Machine learning enables identification of an alternative yeast galactose utilization pathwayMarie-Claire Harrison, Emily J Ubbelohde, Abigail L LaBella, et al.
Plos Genetics|March 17, 2026
Machine learning identifies novel signatures of antifungal drug resistance in Saccharomycotina yeastsMarie-Claire Harrison, David C Rinker, Abigail L LaBella, et al.
Current Biology : CB|November 5, 2022
Contrasting modes of macro and microsynteny evolution in a eukaryotic subphylumYuanning Li, Hongyue Liu, Jacob L Steenwyk, et al.
British Journal of Haematology|April 1, 2015
Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST TrialAdam J Mead, Dragana Milojkovic, Steven Knapper, et al.
Biorxiv : the Preprint Server for Biology|July 14, 2025
Machine learning identifies novel signatures of antifungal drug resistance in <i>Saccharomycotina</i> yeastsMarie-Claire Harrison, David C Rinker, Abigail L LaBella, et al.
Therapeutic Advances in Hematology|July 7, 2025
Clinical outcomes of high-risk patients with polycythemia vera after suboptimal response to first-line therapy who switched to ruxolitinib versus nonswitchers: results from the PV-Switch studySteffen Koschmieder, Clemens Schulte, Eyck von der Heyde, et al.
Haematologica|January 26, 2023
Differential inhibition of T-cell receptor and STAT5 signaling pathways determines the immunomodulatory effects of dasatinib in chronic phase chronic myeloid leukemiaPatrick Harrington, Richard Dillon, Deepti Radia, et al.
Pageof 22